Lilly reports A1C fell 2.2% on retatrutide versus 1.8% on Ozempic 2 mg, but diarrhea and dysesthesia were more common. An FDA filing is planned for early 2027.
Recap by typeshit. Full story at BioSpace.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
Mounjaro and Zepbound still carry Lilly, but neuroscience sales rose 32% in the first half of 2026. Lilly reports third-quarter results on Oct. 29.
That's up from 9% a year ago, and coverage fell to 53% from 57%. 24/7 Wall St. looks at what cash pricing means for Lilly and Novo ahead of earnings.
Loading…